Clinical trial · Interventional
Phase II Trial of Allovectin-7® for Metastatic Melanoma
A Phase II Study of High-Dose Allovectin-7® in Patients With Advanced Metastatic Melanoma
NCT00044356CI-TRIAL-00005181completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this clinical trial is to determine if Allovectin-7®, an experimental gene-based immunotherapy, can shrink melanoma tumors. The trial will also examine if this treatment can improve the time to disease progression.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Melanoma | Melanoma | ALIAS | 0.90 |
| Melanoma | Melanoma | ONTOLOGY_EXACT | 0.98 |
| Metastatic Melanoma | Melanoma | CURATED_BROADER | 0.78 |
| Skin Cancer | Malignant Skin Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Allovectin-7® | Genetic | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
In order to be in this trial, you must meet the enrollment criteria. Below is a list of some of the enrollment criteria. * You have been diagnosed with Stage III or Stage IV melanoma * Your cancer has returned after a prior treatment (e.g. radiation or chemotherapy) or you refused therapy with standard treatment * You are able to carry out your normal daily activities * Your melanoma has not spread to your brain
References
Publications (0)
Data not yet available
No reference posted for this study.